|
|
| (4 intermediate revisions by one user not shown) |
| Line 1: |
Line 1: |
| − | A review of the article by Smoyer-Tomic et al., ‘Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis' <ref name=“Smoyer-Tomic 2012”> Smoyer-Tomic 2012. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/22703603 </ref>
| |
| | | | |
| − | ==Introduction==
| |
| − | Autoimmune idiopathic inflammatory myopathies (IIMs) have the following common characteristics: Auto-immune disorder, no known cause, muscle inflammation, and muscle weakness and consist of three types: polymyositis, dermatomyositis, and sporadic inclusion body myositis. Many studies have not examined IIM, however using data gathered from commercial insurance, Medicaid and Medicare, this study examined how common and frequent IIM is.
| |
| − |
| |
| − | ==Methods==
| |
| − | Data from 2004 - 2008 was gathered from:
| |
| − | # 130 unique commercial insurance companies for outpatient pharmacy claims for people under 65 (14 million enrollees annually)
| |
| − | # Medicare supplemental insurance paid for by employers for retired and working-age recipients (1.6 million individuals)
| |
| − | # Pooled Medicaid healthcare information from 10 states (28 million)
| |
| − | The data was filtered for patients over the age of 18 with an IIM treatment and patients who had a muscle biopsy; incidence and prevalence was then calculated.
| |
| − |
| |
| − | ==Results==
| |
| − | The study identified 2,990 incident cases with 2,477 (83%) were from the commercially insured/Medicare supplemental databases and 513 (17%) were from the Medicaid database with 1,072 had dermatomyositis, 1,784 had polymyositis, and .476 had interstitial myositis. The study also identified 7,155 prevalent patients 39.1% had dermatomyositis, 58.9% had polymyositis, and 9.8% had interstitial myositis.
| |
| − |
| |
| − | ==Discussion==
| |
| − | The data showed that IIM incidence for 2004–2008 for commercial/ Medicare supplemental groups was 4.27 cases per 100,000 py, and 5.23 cases per 100,000 py for Medicaid, with the highest incidence among the polymyositis type (2.46 commercial/Medicare supplemental and 3.53 Medicaid new cases per 100,000 py). Overall, the study shows that in the U.S., IIM incidence will likely range from 3 to 7 new cases per 100,000 py and prevalence for IIM treatment will range from 32,000 to 68,000 per year.
| |
| − |
| |
| − | ==Conclusion==
| |
| − |
| |
| − | ===Comments===
| |
| − |
| |
| − | == References ==
| |
| − |
| |
| − | <references/>
| |
| − | [[Category: Reviews]]
| |
| − | [[Category: Databases, Big Data, and Data Quality]]
| |
